CG Oncology FY2025 EPS Forecast Reduced by Cantor Fitzgerald
Research analysts at Cantor Fitzgerald reduced their FY2025 earnings estimates for CG Oncology in a report issued on Monday, March 31st. Cantor Fitzgerald analyst J. Schimmer now expects that the ...
HC Wainwright Estimates CG Oncology FY2029 Earnings
HC Wainwright issued their FY2029 EPS estimates for CG Oncology in a note issued to investors on Monday, March 31st. HC Wainwright analyst A. Maldonado anticipates that the company will post earnings ...
CG Oncology Looks Attractive At Current Prices (Rating Upgrade)
CG Oncology, Inc.'s promising bladder cancer therapy has strong clinical results, competitive CR rates, and a $69 target ...
CG Oncology to Participate in the 120th American Urological Association Annual Meeting with a Series of Key Presentations and Updates
Durability Results from BOND-003 data will be presented as a late breaker as part of AUA’s Practice-changing, Paradigm-shifting Clinical Trials in Urology - - Additional updates from across CG ...
CG Oncology, Inc. (CGON) Gets a Buy from Morgan Stanley
In a report released today, Sean Laaman from Morgan Stanley maintained a Buy rating on CG Oncology, Inc. (CGON – Research Report), with a price ...
CG Oncology files automatic mixed securities shelf
EDT CG Oncology (CGON) files automatic mixed securities shelfLight Up your Portfolio with Spark:Easily identify stocks' risks and ...
Morningstar4d
CG Oncology to Participate in the 120th American Urological Association Annual Meeting with a Series of Key Presentations and Updates
March 31, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing ...
Nasdaq2d
Relative Strength Alert For CG Oncology
A stock is considered to be oversold if the RSI reading falls below 30. In trading on Tuesday, shares of CG Oncology Inc (Symbol: CGON) entered into oversold territory, hitting an RSI reading of ...
Nasdaq4d
CG Oncology to Participate in the 120th American Urological Association Annual Meeting with a Series of Key Presentations and Updates
Paradigm-shifting Clinical Trials in Urology - - Additional updates from across CG Oncology’s clinical trial program, including translational data, planned - Cretostimogene is an investigational ...